Hikma Pharmaceuticals PLC
Open
SectorHealthcare
1,528 1.13
Overview
Share price change
24h
Min
1512
Max
1534
Income | 165M |
|---|---|
Sales | 41M 1.7B |
P/E Sector Avg | 10.891 50.958 |
EPS | 1.07 |
Dividend yield | 5.65 |
Profit margin | 9.698 |
Employees | 9,400 |
EBITDA | 152M 411M |
Recommendations | Buy |
|---|---|
12 Months Forecast | +10.45% upside |
Dividend yield Sector Avg | 5.65% 2.41% |
|---|---|
Next Earnings | 6 sie 2026 |
Next Dividend date | 17 wrz 2026 |
Next Ex Dividend date | 13 sie 2026 |
Market Cap | -476M 3.2B |
|---|---|
Previous open | 1526.87 |
Previous close | 1528 |
News Sentiment
By Acuity
17%
83%
28 / 342 Ranking in Healthcare
Hikma Pharmaceuticals PLC Chart
Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.
About Hikma Pharmaceuticals PLC
Hikma Pharmaceuticals PLC develops, manufactures, markets, and sells a range of generic, branded, and in-licensed pharmaceutical products. It operates through three segments: Injectables, Generics, and Branded. The Injectables segment provides generic injectable products primarily for use in hospitals. The Generics segment offers oral and other non-injectable generic products for the retail market. The Branded segment offers branded generics and in-licensed products to retail and hospital markets. The company provides its products in various therapeutic areas, including respiratory, oncology, and pain management. It also offers its products in solid, semi-solid, liquid, and injectable final dosage forms. The company operates in the United Kingdom, rest of Europe, North America, the Middle East, North Africa, and internationally. Hikma Pharmaceuticals PLC was founded in 1978 and is headquartered in London, the United Kingdom.